<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01646567</url>
  </required_header>
  <id_info>
    <org_study_id>SHP-141C-002</org_study_id>
    <nct_id>NCT01646567</nct_id>
  </id_info>
  <brief_title>SHP-141C in Plaque Type Psoriasis</brief_title>
  <official_title>A Double-Blind, Within-Subject Randomised, Placebo-Controlled, Proof of Concept, Comparison Study of SHP-141C Topical Cream in Psoriasis, Using the Microplaque Assay.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TetraLogic Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TetraLogic Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and clinical activity of the&#xD;
      SHP-141C topical cream formulations in patients with plaque type psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psoriasis is a chronic, relapsing immunoinflammatory disorder. Chronic plaque psoriasis is&#xD;
      the most common (85% - 90%) type. Cutaneous features of individual plaques include circular&#xD;
      with centrifugal expansion, induration with sharp demarcation from surrounding skin, erythema&#xD;
      and hyperkeratosis. Psoriasis has a negative impact on physical and mental aspects of life&#xD;
      that is similar to other major chronic conditions. The modalities of psoriasis treatments can&#xD;
      be divided into four main categories: topical, phototherapy, systemic drug therapies and&#xD;
      systemic biological treatments. The currently available treatments for psoriasis result in&#xD;
      either disease suppression or disease remission.There are many treatment options for the&#xD;
      management of psoriasis using topical modalities; however all are lacking with respect to&#xD;
      patient satisfaction and durability of treatment. Most current topical treatments, and many&#xD;
      treatments in development, are based on modifications of a steroid structure or on Vitamin D.&#xD;
      Recent research has identified a broad role for histone deacetylase (HDAC) proteins in&#xD;
      numerous signaling pathways critical to cancer cell survival, such as epigenetic inheritance,&#xD;
      gene regulation, mitosis,signal transduction and importantly, inflammation. Theoretically&#xD;
      modulation of HDAC could lead to clinical benefit in inflammatory diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Local Plaque Severity Index (LPSI)</measure>
    <time_frame>Baseline, day 15, day 33</time_frame>
    <description>Measurement of plaque severity including erythema, induration, and desquamation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of patients with adverse events</measure>
    <time_frame>daily to and including Day33</time_frame>
    <description>Adverse event data for each subject will be collected.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Plaque Type Psoriasis</condition>
  <arm_group>
    <arm_group_label>SHP-141C &amp; Placebo &amp; Calcipotriol &amp; Betamethasone Valerate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 100 mg dose of SHP-141C cream at three concentrations (0.5%, 1.0% and 2.0%), a matched placebo cream and two reference treatments: Calcipotriol 0.005% cream and Betamethasone Valerate 0.02% cream, applied topically to a selected plaque on each subject, six times per week over 28 days for a total of 24 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP-141C</intervention_name>
    <description>Topical Cream</description>
    <arm_group_label>SHP-141C &amp; Placebo &amp; Calcipotriol &amp; Betamethasone Valerate</arm_group_label>
    <other_name>SHAPE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to SHP-141C</intervention_name>
    <description>Placebo Topical Cream</description>
    <arm_group_label>SHP-141C &amp; Placebo &amp; Calcipotriol &amp; Betamethasone Valerate</arm_group_label>
    <other_name>Placebo to SHAPE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone Valerate</intervention_name>
    <description>Topical cream, 0.02%</description>
    <arm_group_label>SHP-141C &amp; Placebo &amp; Calcipotriol &amp; Betamethasone Valerate</arm_group_label>
    <other_name>Celestone-M</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol</intervention_name>
    <description>Topical cream, 0.005%</description>
    <arm_group_label>SHP-141C &amp; Placebo &amp; Calcipotriol &amp; Betamethasone Valerate</arm_group_label>
    <other_name>Daivonex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Mild to moderate chronic plaque-type psoriasis.&#xD;
&#xD;
          2. psoriasis of at least one year.&#xD;
&#xD;
          3. Stable disease for at least two weeks prior to the commencement of study treatment.&#xD;
&#xD;
          4. One nominated target lesions must have areas of at least 86 x 57 mm2.&#xD;
&#xD;
          5. BMI of less than 35 kg/m2. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Dermatological Conditions&#xD;
&#xD;
               -  Subjects with erythrodermic, guttate, palmar, plantar or generalised pustular&#xD;
                  forms of psoriasis.&#xD;
&#xD;
               -  Subjects with scalp, palmar or plantar psoriasis only.&#xD;
&#xD;
               -  Subjects with any skin condition other than psoriasis, in particular eczema,&#xD;
                  cutaneous infections, significant sun damage or an inherited skin disorder (other&#xD;
                  than psoriasis).&#xD;
&#xD;
          2. Concurrent Medical Conditions&#xD;
&#xD;
               -  History of clinically significant intercurrent disease of any type (other than&#xD;
                  psoriasis).&#xD;
&#xD;
               -  A history of moderate or severe asthma during the last 10 years.&#xD;
&#xD;
               -  Major chronic inflammatory disease .&#xD;
&#xD;
               -  Congenital immunodeficiency or cancer prone syndrome.&#xD;
&#xD;
               -  History of abnormal bleeding tendencies or thrombophlebitis, or a history of&#xD;
                  Hepatitis B, Hepatitis C or HIV infection.&#xD;
&#xD;
               -  History of malignancy (other than adequately treated skin carcinoma or&#xD;
                  carcinoma-in-situ of the cervix).&#xD;
&#xD;
          3. Laboratory Status&#xD;
&#xD;
               -  Any evidence of organ dysfunction, which is confirmed on re-examination to be&#xD;
                  clinically significant (i.e. in the opinion of the Medical Officer would&#xD;
                  jeopardise the safety of the subject or impact on the validity of the study&#xD;
                  results),&#xD;
&#xD;
               -  A creatinine clearance of less than 75 mL/min.&#xD;
&#xD;
               -  Liver function test &gt; 1.5 x upper limit of normal other than an isolated&#xD;
                  bilirubin.&#xD;
&#xD;
               -  Hepatitis B surface antigen, Hepatitis C antibody, HIV antibodies.&#xD;
&#xD;
          4. Treatment with any of the following within 4 weeks prior to the commencement of study&#xD;
             treatment and for the duration of the study:&#xD;
&#xD;
               -  Systemic retinoids.&#xD;
&#xD;
               -  Immunosuppressant agents (e.g. methotrexate, cyclosporine, azathioprine,&#xD;
                  thioguanine prednisone, prednisolone, hydroxyurea or mycophenolate mofetil).&#xD;
&#xD;
               -  Phototherapy or photochemotherapy.&#xD;
&#xD;
               -  High potency topical corticosteroids.&#xD;
&#xD;
               -  &quot;Alternative medicine&quot; treatments for psoriasis.&#xD;
&#xD;
               -  Prolonged sun exposure or tanning bed use, which may in the opinion of the&#xD;
                  Investigator, modify disease activity.&#xD;
&#xD;
          5. Topical treatment of the 2 target lesions with any of the following within 2 weeks&#xD;
             prior to commencement of study treatment and for the duration of the study&#xD;
&#xD;
               -  Moderate potency topical corticosteroids.&#xD;
&#xD;
               -  Vitamin D analogues and topical retinoids.&#xD;
&#xD;
               -  Keratolytics, coal tar and dithranol.&#xD;
&#xD;
          6. Concurrent Medications Subjects have received or anticipate receiving a new medicine&#xD;
             (prescription, over-the-counter or herbal), given systemically or topically, within 14&#xD;
             days prior to the start of dosing. Subjects may be enrolled if stable on existing&#xD;
             therapy (having been on it for at least 60 days) as determined by the Principal&#xD;
             Investigator.&#xD;
&#xD;
          7. Hypersensitivity History of allergy and/or hypersensitivity to any of the stated&#xD;
             ingredients of the formulations or other topical agents. A known hypersensitivity to&#xD;
             lignocaine, or all surgical dressings that may be used in the study procedures.&#xD;
&#xD;
          8. Females who are lactating, pregnant or planning to become pregnant.&#xD;
&#xD;
          9. Drug and Alcohol Abuse History of, or current evidence of, abuse of alcohol or any&#xD;
             drug substance, licit or illicit, or positive urine drug and alcohol screen for drugs&#xD;
             of abuse and alcohol.&#xD;
&#xD;
         10. Psychiatric Disorder History of any psychiatric illness which may impair the ability&#xD;
             to provide written informed consent&#xD;
&#xD;
         11. Participation in a research study within 30 days of the start of dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Foley</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Alfred</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nucleus Network Limited</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 11, 2012</study_first_submitted>
  <study_first_submitted_qc>July 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <last_update_submitted>July 10, 2014</last_update_submitted>
  <last_update_submitted_qc>July 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

